Physician profile
Kurt D Johnson
NPI 1598754913
$6,381.53
in general payments reported to CMS, 2019-2025
45 companies · $830 in 2025
The $830 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $701 · 2020: $937 · 2021: $1,377 · 2022: $906 · 2023: $503 · 2024: $1,127 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,460.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $979.16 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $943.38 | 2019-2025 | Farxiga |
| Abbvie INC. | $677.05 | 2020-2025 | |
| Novo Nordisk INC | $648.82 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $366.61 | 2020-2025 | Freestyle Libre 3, Freestyle Libre, Eterna |
| Pfizer INC. | $314.99 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $296.32 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.43 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Lilly USA, LLC | $243.95 | 2020-2025 | Jardiance |
| Astellas Pharma US INC | $129.60 | 2020-2021 | |
| Eisai INC. | $126.05 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.84 | 2024-2025 | Caplyta |
| Allergan, INC. | $87.15 | 2019-2020 | |
| Amgen INC. | $84.74 | 2024-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.40 | 2019-2025 | Xifaxan, Trulance |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.